With Lib­tay­o's sec­ond ap­proval, Re­gen­eron digs deep­er in­to PD-1 der­ma­to-on­col­o­gy niche

With the sixth check­point in­hibitor to en­ter the US mar­ket, Re­gen­eron ex­ecs have in­sist­ed that they can carve out a re­spectable mar­ket share for Lib­tayo by go­ing to in­di­ca­tions that oth­ers haven’t. Late Tues­day, the big biotech made an­oth­er step to­ward that goal.

The PD-1 drug, al­so known as cemi­plimab, is now in­di­cat­ed for pa­tients with both fla­vors of ad­vanced basal cell car­ci­no­ma — in ad­di­tion to metasta­t­ic cu­ta­neous squa­mous cell car­ci­no­ma.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.